pharmacopeia

Mechanism of action

Sourced from openFDA

Mechanism-of-action class: X-Ray Contrast Activity.

Approval history

Sourced from openFDA
  • Nov 27, 2024NDANDA216016Bracco

FAERS reports

View JSON
Reference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. Counts reflect reporting volume — how often a reaction was reported, not how often it occurs. For decision-grade use, consult openFDA and the FAERS Public Dashboard directly.
1,241 total reports matchedLatest report Share = reports listing the reaction ÷ total matched reports. Rows can sum to >100% because a single report often lists multiple reactions.
  1. 1Rash Maculo-papular20216%
  2. 2Drug Reaction With Eosinophilia And Systemic Symptoms16513%
  3. 3Acute Kidney Injury13211%
  4. 4Eosinophilia1068.5%
  5. 5Toxic Skin Eruption967.7%
  6. 6Acute Generalised Exanthematous Pustulosis927.4%
  7. 7Pruritus756.0%
  8. 8Erythema534.3%
  9. 9Pyrexia524.2%
  10. 10Rash463.7%
  11. 11Hypotension362.9%
  12. 12Off Label Use342.7%
  13. 13Anaphylactic Shock332.7%
  14. 14Dyspnoea332.7%
  15. 15Urticaria312.5%

Clinical trials

View JSON

The 10 most recently updated of 16 ClinicalTrials.gov registrations naming Iomeprol as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

Frequently asked questions

How does Iomeprol work?
Mechanism-of-action class: X-Ray Contrast Activity.
What class of drug is Iomeprol?
Iomeprol is classified as Watersoluble, nephrotropic, low osmolar X-ray contrast media, Radiographic Contrast Agent, X-Ray Contrast Activity.
Note. Data for iomeprol is illustrative MVP content compiled from public sources. pharmacopeia is for educational and informational use only and is not a substitute for professional medical advice.

Search pharmacopeia

Search drugs, classes, and ingredients